Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

facturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there is significant uncertainty regarding the level and timing of sales of ST-246 and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. We cannot predict with certainty when SIGA will commence delivering any product or will begin recognizing profit on the sale thereof and there can be no assurance that any profits received by SIGA and paid to us will be significant. Furthermore, the Court of Chancery may grant SIGA's motion for reargument and the Court of Chancery decision could be appealed by SIGA, and there can be no assurances that the decision will not be reversed or that the remedy will not otherwise be modified. In addition, to the extent that there is an appeal, we cannot predict how long that will delay the receipt of payments, if any, from SIGA. Further, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for SparVax ™, Valortim® and our rBChE product. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com. -- Tables Follow --PHARMATHENE, INC.CONDENSED CONSOLIDATED BALANCE SHEETSSeptember 30,December 31,2011Unaudited2010ASSETSCurrent assets:Cash and cash equivalents$

10,406,076$

11,785,327Restricted cash100,000100,000Accounts receivable, net4,039,7015,367,130Other re
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Palm Beach County, Florida (PRWEB) August 27, 2014 ... & Company Inc. (SCI) is announcing the creation ... board’s priority is to take the SCI’s philosophy ... insuring the company’s research and development actions are ... interpretations. , This new Scientific Advisory Board provides ...
(Date:8/27/2014)... After the boom of the energy ... beverage craze is going to be the stress relief ... use Stress Relief energy pattern which can be applied ... a beverage, including minerals, herbs and liquids. Stress Relief ... power into rapid recovery and helping to adapt more ...
(Date:8/27/2014)... Remcom announces an update to XFdtd® ... the biomedical industry. The central biomedical addition in ... to the Bio-Pro version of the software. XFdtd ... calculate the biological effects of electromagnetic fields. In ... versions to expand engineers’ post-processing options. , The Biological ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Budding ... Cleveland's University School participated in the ... Western Reserve University’s School of Medicine . ... with an unparalleled professional experience in the sciences ... of Medicine faculty and students for both academic ...
Breaking Biology Technology:New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... ... ... , ... OXFORD, England and LANGHORNE, Pennsylvania, ...
... ... ... , ... ...
... , ... ... ... ...
Cached Biology Technology:EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 2EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 3EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 2Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 3Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 5Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 6Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 7MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 2MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 3MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 4
(Date:8/27/2014)... 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... in the offering consists of 2,000 shares of common ...
(Date:8/27/2014)... of North America,s megafauna mastodons, short-faced bears, giant ... disappeared close to 13,000 years ago at the ... massive extinction has long been debated by scientists who, ... A group of scientists, including UC Santa Barbara,s James ... posited that a comet collision with Earth played a ...
(Date:8/27/2014)... of the human genome was unveiled today in the ... comparison yet of how the genomes of the fruit ... appearing August 28 in in the journal Nature ... species, genomes is "read out," and how their DNA ... add billions of entries to a publicly available archive ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... arrhythmias are killers. They strike without ... about 10 percent of all deaths in the ... molecular mechanism associated with arrhythmias. Their findings, reported ... could lead to novel arrhythmia treatments., "The current ...
... expedition in 1965 to trap moths on Mount Kinabalu in ... groundwork for a study of the impacts of climate change. ... has repeated the survey 42 years later, and found that, ... over the intervening years to cope with changes in climate. ...
... and food research, is coordinating the international TXOTX ... fundamental aim of this project is to collate ... programs from the different regions in the world,s ... cooperation between countries, regional fisheries organisations and other ...
Cached Biology News:Studies point to novel target for treating arrhythmias 2Studies point to novel target for treating arrhythmias 3The global impact of climate change on biodiversity 2TXOTX, coordinated international project to contribute to sustainability of the marine resources 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
... Monoclonal Antibody, Unconjugated Applications: ... ICC: Use at an assay dependent dilution. WB: ... ug/ml, this concentration is determined using a whole ... kDa. Not tested in other applications. Optimal ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Biology Products: